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vices is the need for surgical insertion and eventually
surgical removal of the implant. This is necessary since

PREPARATION OF BIODEGRADABLE
MICROSPHERES USEFUL AS CARRIERS FOR
MACROMOLECULES

the devices are composed of materials which are nonde

gradable.
Microspheres containing proteins have been prepared
from polyacrylamide, acryloylated dextran and

BACKGROUND OF THE INVENTION
(1) Field of the Invention
The present invention relates generally to the ?eld of

acryloylated starch. Polyacrylamide beads can meet

different purposes in vitro, but their nondegradability

biodegradable polymers for the controlled release of
biologically active agents therefrom. More particularly,

prevents their use in humans. Reported data on polysac
charide particles show that an ef?cient crosslinking has
been achieved only at a high degree of derivatization
(D.D. about 0.1 to 0.3). A high DD. is disadvantageous
as it decreases the biocompatibility of the polymer. A
high D.D. also leads preferentially to the intramolecular

the present invention relates to a process for preparing

biodegradable polymers in the form of spherical parti
cles of controlled size. The process is designed to allow

the biodegradable polymer particles to contain incorpo

rated biologically active agents and to allow controlled 15 reaction of polymerizable groups instead of the inter- ’

release of these agents while allowing targeted delivery

molecular reaction between different polymer chains,

via injection or inhalation.

which results in a heterogenous microporous structure.
The use of the crosslinking agent bisacrylamide is not
considered desirable, since it generally results in the

(2) Background of the Prior Art
The use of proteins and peptides as therapeutic agents

has been recognized and their position within the phar 20 formation of crosslinked hydrocarbon gels, which nei
maceutical arrnamentarium is growing due to their in

ther dissolve nor degrade even after degradation of the

creasing availability. This availability is primarily due

polysaccharide component.

to recent advances in genetic engineering and biotech

The recent advances in the incorporation of drugs

nology. Unfortunately, the use of proteinaceous drugs
by conventional routes of administration is generally

25

hampered by a variety of delivery problems. Nonpar
enteral routes of administration, i.e., oral and percutane
ous, are inef?cient primarily due to poor absorption of

proteinaceous drugs into the bloodstream and degrada
tion of such drugs in the gastrointestinal tract. Rapid
proteolytic inactivation of the proteinaceous drug also
occurs when the drug is administered parenterally thus

decreasing its bioavailability. In addition, when admin
istered by the parenteral route, the host’s immune sys
tem is activated thereby potentially setting off a series of
undesirable immune reactions.
In view of the foregoing, considerable effort has been
devoted to developing alternative systems for paren
teral delivery of peptides and proteins to obviate the
problems associated with prior art administration tech
niques. For instance, implantable devices have been cast
or molded from poly-(hydroxyethyl)methacrylate, pol

into microparticulate carriers has attracted a great deal
of attention because it combines features of matrix-con
trolled release with those of injectable forms. In addi
tion to controlled release, these microspherical carriers

offer “?rst stage” physical targeting, that is, physical
localization of the drug carrier in the proximity of the
target tissue and cells. Localized administration of the
therapeutic agent allows for not only more ef?cient
drug therapy but also minimizes the opportunity for
adverse systemic effects.
In preparing microspheres in the size range of 1 pm
35
30

to 20 um, homogenous systems are more suitable than

heterogenous systems for casting implants. In the ho
mogenous system, proteins are co-dissolved in the same
solvent as the material of the matrix. Furthermore, in

order to preserve the biological activity of the macro

molecules, aqueous systems are generally preferred. In
this regard, biodegradable hydrophilic polymers can be

yvinyl alcohol, ethylene-vinylacetate copolymer

chosen as matrix material provided that they can be
solidi?ed or crosslinked by a mechanism which does
have been embedded in those devices. A typical method 45 not involve a chemical modi?cation and/or denatura
tion of the incorporated macromolecule such as a pro
of preparation involves suspending a powder of a mac
teinaceous agent.
romolecular drug such as a solid protein or peptide in a
It is known that crosslinked hydrophilic gels can be
solution containing the polymer. The entire composi
obtained utilizing techniques of free-radical polymeriza
tion is then cast or molded into the desired size and
tion. To some extent, the problems identi?ed above are
shape either by evaporating the solvent or by vulcaniza
similar to those found in the preparation of graft biode
tion. A sustained release of macromolecules from these

(EVA) and silicone elastomer. Macromolecular drugs

devices has been demonstrated. The simplicity of the

gradable polymers, that is, polymers containing vinylic

foregoing prior art method is its primary advantage.
However, one disadvantage of hydrophobic poly

groups with the encapsulation of biologically active

macromolecules, thus, only that portion of the drug

patents disclose methods for the preparation of graft
copolymers of polysaccharides and vinylic monomers.
These patents were directed to improving the physical
properties of the polysaccharides within each composi
tion. Process conditions used to achieve these improve

materials therein.
mers such as those prepared from EVA and silicon, is 55
Examples of prior art patents include US. Pat. Nos.
that those polymers are not permeable to hydrophilic
4,131,576, 3,687,878, 3,630,955 and 3,950,282. These

which communicates with the surface of the implant,
either directly orvia contact with other drug particles,
can be released. Thus, the drug present nearer the inte
rior of the implant and completely surrounded by the
polymer matrix is unable to ever be released and never
exerts its therapeutic effect. Addition of polar additives _

ments included the use of elevated temperatures, highly
reactive monomers or organic solvents. However, each
increases penetration of water in these hydrophobic
of the foregoing parameters are harmful to biologically
materials and helps to dissolve the protein, but they are 65 active macromolecules and thus are unsuitable in the
not quite inert to the protein, as are the polar organic
practice of the present invention.
solvents used for casting from PHEMA and PVA. An
The prior art also discloses procedures for encapsula
other disadvantage associated with these types of de
tion of a core material in a polymer capsule. US. Pat.

3
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polyhydroxy polymers by the addition of strong acids

4

It is also an object of this invention to produce micro

No. 4,382,813 discloses the the production of a capsule
wall by the gelation of polysaccharide gums, such as
alkali-metal alginates, with bivalent metal cations. US.
Pat. No. 4,344,857 discloses the gelation of xanthates of

spherical carriers from which macromolecular agents
are released under in-vivo conditions at a predictable
rate.
5

and coupling agents. US. Pat. No. 3,567,650 achieves a

similar result by lessening the solubility of certain poly

meric materials using increasing temperature.
Other mechanisms are based on the principle of com

plex coacervation using at least two colloids of opposite

electrical charge and oxidation products of polysaccha
rides as crosslinking agents as disclosed in U.S. Pat. No.

4,016,098. Yet another procedure employs interfacial
crosslinking of the wall-forming polymer by reactive
bifunctional crosslinking agents dissolved in oil droplets

It is yet another object of this invention to produce
microspherical carriers of biologically active macro
molecules which possess a potential for controlling the
rate of biodegradation of the matrix so that the release
of the macromolecular agents can be regulated by the
biodegradation of the matrix.
A further object of the present invention is to pro
duce microspherical carriers of biologically active mac
' romolecules which possess a potential for controlling

the rate of biodegradation of the matrix by adjusting the
matrix properties thereby controlling both release of the

macromolecular agent and existence of the matrix in the
tissue as well as assuring the biodegradation of the ma
trix into nontoxic soluble products which are metabo
lized and/0r excreted.
encapsulated according to the prior art are mostly 20 A still further object of the present invention is to
provide a microspherical drug delivery system which
water insoluble solids or oil droplets and compounds
allows targeting of drugs or other agents to speci?c host
dissolved therein, e.g., dyes, pigments or biologically
tissues or cells via injection or inhalation providing high
active low-molecular-weight compounds like herbi
localized concentrations, sustained activity, systemic
cides.
US. Pat. No. 4,352,883 teaches a method for encap 25 administration and treatment, thereby minimizing unde
sirable systemic effects of toxic drugs administered di
sulation of core materials such as living tissues or indi
rectly into the circulation.
vidual cells in a semipermeable membrane. The mem
These and similar objects, advantages and features
brane is permeable for small molecules but not permea
ble to large molecules. This patent also utilizes the gela
are accomplished according to themethods and compo
which are encapsulated as taught in U.S. Pat. No.

4,308,165. Other examples of the prior art which offer
similar teachings include US. Pat. Nos. 4,078,051,
4,080,439, 4,025,455 and 4,273,672. Materials which are

tion of certain waterssoluble gums by the action of mul 30 sitions of the following description of the present inven
tion.
tivalent cations.

US. Pat. No. 4,038,140 discloses the procedure for
BRIEF DESCRIPTION OF THE DRAWINGS
binding of biologically active proteins onto an insoluble
FIG. 1 depicts an overall scheme for preparation of
carrier by reacting the proteins in an aqueous phase
with a carrier comprising an activated polysaccharide 35 the biodegradable microspheres of the present inven

having a hydrophilic graft copolymer incorporated

tion.
FIG. 2 represents a more detailed view of the micro

therein. That patent is directed to the preparation of

sphere prepared by the process depicted in FIG; 1.
FIG. 3 depicts the cumulative release of alpha-l

insoluble carriers containing covalently bound proteins
with application in biochemical reactors.
Yet another example of the prior art, US. Pat. No.
4,094,833, teaches a procedure for preparation of

40

microspheres.

copolymerizates of vinylic group containing dextran
and divinyl compounds, optionally also monovinyl
compounds, in the form of three-dimensional gel net

works. The resulting crosslinked dextran-vinylic gels

45

can be used for separation purposes.

BRIEF DESCRIPTION OF THE PREFERRED
EMBODIMENTS
The present invention provides a process for the

incorporation of sensitive biologically active macro
molecules into a biodegradable matrix. The biodegrad
able matrix is prepared by the copolymerization of a

In spite of the numerous teachings of the prior art, the
prior art does not offer a method for obtaining encapsu

lated or entrapped biologically active macromolecules
such as proteinaceous agents in spherical microparticles
of controlled size ranges. Nor does the prior art suggest
a procedure for allowing microspheres to have the
potential to control the rate by which the biologically

vinyl derivative of biodegradable hydrophilic polymer
containing at least two vinyl groups per polymer chain
with a monovinyl water-soluble monomer. The biode

gradable matrix is a three-dimensional gel network in
which biologically active macromolecules are physi

active macromolecule is released or for modulating the

rate by which the matrix is degraded in vivo.

proteinase inhibitor from hydroxyethyl starchpolya
crylamide microspheres in pg of protein per mg of

55

cally entrapped. The biodegradable matrix is particu

larly well-suited for the parenteral route of administra
SUMMARY OF THE INVENTION
tion.
It is, therefore, the object of this invention to provide
According to the present invention, the biodegrad
a process for the incorporation of sensitive biologically
able hydrophilic polymer component of the matrix can
active macromolecules, preferably peptides and prote 60 be selected from a variety of sources including polysac
ins, into a biodegradable and biocompatible matrix
charides, proteinaceous polymers, soluble derivatives of
under conditions sufficiently mild to retain the biologi
polysaccharides, soluble derivatives of proteinaceous

polymers, polypeptides, polyesters, polyorthoesters,

cal activity of the incorporated macromolecular agents.
It is another object of this invention to provide for a

matrix, containing pharmacologically active macromol
ecules, in the form of spherical particles of controlled
size, preferably having a diameter in the range of about
0.5 pm to about 500 pm.

and the like.
65

The polysaccharides may be poly-1,4-glucans, e.g.,
starch glycogen, amylose and amylopectin, and the like.
Preferably, the biodegradable hydrophilic polymer is a
water-soluble derivative of a poly-1,4-glucan, including

5
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hydrolyzed amylopectin, hydroxyalkyl derivatives of
hydrolyzed amylopectin such as hydroxyethyl starch

biodegradable hydrophilic polymer.

(HES), hydroxyethyl amylose, dialdehyde starch, and

The degree of derivatization (DD) of the biodegrad
able hydrophilic polymer by the vinyl groups is such,

the like.
Proteinaceous polymers and their soluble derivatives

that they are at least two vinyl groups per average

include gelation biodegradable synthetic polypeptides,
elastin, alkylated collagen, alkylated elastin, and the
like.

polymer chain, preferably, at least three vinyl groups
per average polymer chain. The upper limit of DD is

given by the desired density of crosslinking as discussed

'

Biodegradable synthetic polypeptides include poly

(N-hydroxyalkyD-L-asparagine,

6

glycidyl esters with hydroxyl or amino groups of the

poly-(N-hydroxy

below. It should also be noted that the minimum DD,
0 when expressed in moles of vinyl groups per mole of

aIkyD-L-glutamine, copolymers of N-hydroxyalkyl-L

monomer units of biodegradable hydrophilic polymer
also depends on the molecular weight of the biodegrad

asparagine and N-hydroxyalkyl-L-glutamine with other
amino acids. Suggested amino acids include L-alanine,

able hydrophilic polymer.

L-lysine, L-phcnylalanine, L-leucine, L-valine, L-tyro
sine, and the like.

The monovinyl monomer has two functions. First, it
15 is intended to facilitate the propagation reaction of the

growing radical by lessening steric hindrance during

De?nitions or further description of any of the fore
going terminology are well known in the art and may be

the polymerization of the macromolecular vinyl deriva
tives. This obviates the necessity of a high degree of

found by referring to any standard biochemistry refer
ence text such as “Biochemistry” by Albert L. Lehn

derivatization of the starting biodegradable hydrophilic

inger, Worth Publishers, ‘Inc. and “Biochemistry” by

polymer. And second, it is intended to introduce into
the gel structure or matrix a nondegradable component
which can participate in the regulation of the degrada

Lubert Stryer, W. H. Freeman and Company, both of
which are hereby incorporated by reference.

The aforementioned biodegradable hydrophilic poly

tion rate of the matrix.
The ratio of the monofunctional monomer propaga

mers are particularly suited for the methods and compo

tor to derivatized biodegradable hydrophilic polymer is
chosen such, that during the polymerization, short lin

sitions of the present invention by reason of their char
acteristically low human toxicity and virtually com
plete biodegradability. of course, it will be understood

ear chains of hydrocarbon polymers are produced

that the particular polymer utilized is not critical and a

which are in fact crosslinked by degradable hydrophilic

variety of biodegradable hydrophilic polymers may be

polymer chains. This assures that substantially the en
tire matrix of microspheres can be degraded in vivo to

utilized as a consequence of the novel processing meth

low molecular weight soluble products.
The ratio between the biodegradable hydrophilic

ods of the invention.
The three dimensional network or gel matrix accord
ing to the present invention is obtained by the free-radi

polymer component to the vinyl monomer component

cal polymerization of the biodegradable hydrophilic

may be in the range of about 1:5 up to about 40:1 based

polymer containing at least two vinyl or substituted

on a weight basis. Preferably, the ratio is in the range of

vinyl groups with an additional monovinylic monomer.

about 2:1 to about 20:1.
The monovinyl monomer is designed to facilitate the

The vinyl derivatives of the biodegradable hydro
philic polymer include derivatives containing groups of
the formula (I):

propagation reaction of the growing radical during
40

polymerization thereby obviating the necessity of high
derivatization of starting polysaccharide with polymer

izable groups. The monovinyl monomer also introduces
in the polymer matrix other functional groups, e.g.,
negatively or positively charged, which can participate
wherein R1 is a hydrogen atom or methyl group; n is 0,
in the control of drug release. Typical functional groups
l or 2; and X is a radical having the formula
45 which may participate in the control of drug release
CH2=CRt—(CH2)n—X

(I)

include carboxyl, amino, dialkylamino, dihydroxyalk
ylamino, and the like. The presence of these positive or

negative charges provide ion-exchange properties to
wherein R2 represents the above-mentioned biodegrad
able polymer which contains at least two vinyl or sub

stituted vinyl groups per average polymer chain. Thus,
. X represents an ether, secondary amine, ester or amide

bridge between the group of formula (I) and the biode

gradable hydrophilic polymer. Therefore, typical exam
ples of vinyl substituents include vinyl, allyl, acryloyl,
methacryloyl, acrylamido and methacrylamido groups.
The vinyl derivatives of the biodegradable hydro
philic polymer can be prepared in a variety of ways well
known in the prior art. One suggested approach is the 60

preparation of vinyl and allyl ethers by the reaction of
vinyl alkylhalides, allylhalides, vinylglycidyl ethers or
allylglycidyl ethers with alkaline solutions of the se

lected biodegradable hydrophilic polymer containing

the matrix.
The monovinyl monomer may be selected from the
group of hydrophilic esters and/or amides of acrylic or

methacrylic acids, water-soluble vinyl derivatives,
acrylic acid, methacrylic acid, and the like. Typical
examples of hydrophilic esters and/or amides of acrylic
or methacrylic acids include acrylamide, methacrylam

ide, 2-hydroxyethyl methacrylate, Z-hydroxypropyl
methacrylamide, N-methylacryloyl-tris-hydroxyme
thylaminomethane,
N-acryloyl-N'-dimethylamino
propylamine, 3-N,N-dimethylaminopropylmethacryla
mide, N-alkylmethacrylamide glyceryl monomethacry
late, and the like. Suitable water-soluble vinyl deriva

tives include N-vinylpyrrolidone, N-vinylimidazole,
p-vinylbenzoic acid, vinylpyridine, and the like.
Suitable biologically active macromolecules intended

either hydroxyl or amino groups. In a like manner, 65 to be used in the practice of the present invention in
derivatives containing either ester or amide linkages can
clude hormones, proteins, peptides, vaccines, enzymes,
be prepared by reacting acryloyl chlorides, methacryl
enzyme inhibitors and other biologically active macro

oyl chlorides, acryloyl glycidyl esters or methacryloyl

molecules. A suggested inhibitor is alpha-l-antitrypsin

7
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include amino acid metabolizing enzymes in the treat

ministered alone or in admixture with appropriate phar
maceutical diluents, carriers, excipients or adjuvants

ment of neoplasia, ?brinolytic enzymes, interferon,

suitably selected with respect to the intended route of

(ATT), an a-proteinase inhibitor. Additional examples

administration and conventional pharmaceutical prac
growth hormone, antigens for desensitization, immuno
globulins and Fab-fragments of immunoglobulins. The 5 tices. These inert pharmaceutically acceptable adju
present invention is not intended to be limited to any of

vants are well known in the art. For example, for paren
teral injection, dosage unit forms may be utilized to

the foregoing and other types of biologically active
macromolecules are equally suitable in the practice of
the present invention.
The biologically active macromolecules remain free

suitable sterile aqueous or non-aqueous solutions or

within the polymer matrix, that is, there are no chemical

suspensions, optionally containing appropriate solutes

accomplish intravenous, intramuscular or subcutaneous

administration, and for such parenteral administration,

bonds between the macromolecule or some other group

to effect isotonicity, will be employed. Likewise for

within the microsphere. Thus, the macromolecule does

inhalation dosage forms, for administration through the

not require the breakage of a chemical bond to be re
leased. Release occurs through diffusion out of the mi

crosphere or biodegradable erosion of the polymer.
The polymerization reaction according to the present
invention is conducted under suitable conditions for
free radical polymerization. The reaction is always con
ducted in aqueous solution. Suitable free radical initia
tors are redox type initiators. The polymerization reac
tion is preferably conducted using free radical initiators
to produce free radicals under mild conditions such as a

temperature of approximately 0° C. However, the tem
perature of the polymerization reaction may range from
about 0° C. to about 50° C. The preferred temperature
at which to conduct the polymerization reaction ranges
from about 0° C. to about 30° C.

It is a particularly advantageous feature of the present

mucous membranes of the nose and throat or bronchio

pulmonary tissues, suitable aerosol or spray inhalation
compositions and devices will be utilized.

The foregoing methodology allows for the prepara
tion of microspheres in controlled size ranges under
conditions sufficiently mild to preserve the biological
activity of functional macromolecules. In addition, the

foregoing methodology allows for the potential for
controlling the release of the drug by controlling the
crosslinking density and the rate of degradation via
selecting the derivatization degree of the starting poly
saccharide and matrix composition.
The polymerization may be conducted by any poly
merization process known in the art, however, another
important feature of the present invention is the fact
that the polymerization can be conducted using a bead

manufacturing procedure that, starting from the disso

polymerization technique. According to the convenient

lution of the macromolecule of interest until dispensing

process described in the present invention, the deriva
tized biodegradable hydrophilic polymer, the monovi
nyl monomer and the biologically active macromole
cule which is to be incorporated therein are codissolved

the ?nal microspheres in vials, the entire process can be

carried out at temperatures near 0° C. in order to mini

mize the denaturation effect on the macromolecule.

Typical redox type initiators include ammonium persul
fate, hydrogen peroxide, benzoyl peroxide, and the like.
It is also advantageous to use a free radical initiator

along with a compound which forms with the initiator
a redox system and accelerates the formation of radi

in an aqueous buffer of appropriate pH and ionic

strength which is suitable for preserving the biological
activity of the macromolecular agent, usually together
with one component of the initiator system. Either oxi
dative or reductive types of initiators are useful.

cals. Examples of the second compound of the initiator 40 The aqueous solution is then deoxygenated by purg
system include N,N,N'N’-tetramethylethylenediamine,
ing with N2 and emulsi?ed in a deoxygenated water

ascorbic acid, N,N=dimethylamino-p-toluidine, S-dime
thylaminopropionitrile, sodium metabisul?te, and the
like.
During the polymerization reaction, linear chains of 45

immiscible organic liquid, preferentially composed of
higher aliphatic hydrocarbons such as hexane, heptane,
octane, cyclohexane, or their higher homolo gs and their
mixtures. In order to facilitate the emulsiflcation and

the biodegradable hydrophilic polymer. It is thus im

formation of a water-in-oil emulsion, appropriate emul
sifying agents are added to the continuous organic

portant that a monovinyl monomer is used during the
polymerization reaction to ensure that only linear

phase. Typical emulsifying agents include sorbitan ole
ates, polyethylene glycol ethers, polyoxyethylene sorbi
tan esters, polyoxyethylene polyoxypropylene alcohols,

vinylic polymer are formed which are crosslinked with

chains of nondegradable hydrocarbon polymers are
formed. Thus, the use of the monovinyl monomer en

sures that the degradation of the biodegradable compo
nent which is responsible for the crosslinking will allow

for the formation of totally soluble degradation prod

and the like.
After obtaining an emulsion having a suitable size

range of aqueous droplets, the polymerization is begun
by addition of the other component of the initiator

ucts. The monovinyl monomer of the present invention,

system to the emulsion. When a water soluble com

since it is only a monomer, will have a low molecular

pound is used, the oxidant component of the initiator
system, e.g., ammonium persulfate and the like, is in the
aqueous dispersed phase, then the second component is

weight compared to the biodegradable polymer. It has

been speculated that if the molecular weight of the
monomer exceeds 400, then steric hindrance is possible.
a reductant soluble in the continuous phase, e.g.,
Thus, it is recommended for purposes of the present 60 N,N,N’,’-tetramethylethylenediamine and the like. The
invention that the monovinyl monomer have a molecu~
microspheres formed by the polymerization of the aque
lar weight of less than 400.
ous droplets of the emulsion are cleansed by decantation
The drug delivery system in accordance with the
and washed with an appropriate water-immiscible or
present invention is ideally suited for administration by
ganic solvent and then freeze dried. Suitable organic
parenteral or inhalation routes. It will be appreciated by 65 water-immiscible solvents include cyclohexane, ben
those skilled in the art that the porous microspheres of
zene, cyclohexanone, and the like.
the present invention containing incorporated drugs for
Following another procedure according to the pres
release to target cells or tissues, therefore, may be ad
ent invention, the microspheres after washing with

4,741,872
organic solvent can be redispersed in water or an aque
ous buffer, washed with the buffer and freeze-dried

from an aqueous suspension. The biologically active

10

density of 0.02 to 0.15 moles of vinyl groups per moles
of monomer units will produce approximately a ten-fold
difference in the release rate of the protein having a

compound, e.g., peptide, protein, and the like, while

molecular weight of about 50,000.

co-dissolved in the aqueous dispersed phase, is en

It will be appreciated that the concentrations, tem
peratures and ratios referred to hereinabove and in the
examples set forth operable ranges and that other nu

trapped in the crosslinked polymer network during
polymerization and can be released in vivo essentially

by the diffusion through the polymer network or fol
lowing the degradation of the matrix.
A particularly advantageous feature of the foregoing
process, and irrespective of the particular polymeriza
tion technique selected, is that the microspheres can be
prepared in a variety of size ranges generally ranging

merical expressions may apply as different solvents,
polymers, monomers, macromolecules, etc. are se

lected.

The following non-limiting examples are offered in
order that those skilled in the art may more readily

understand the present invention and the speci?c pre

from about 0.5 pm to about 500 pm in diameter. Size
ferred embodiments thereof. Unless indicated other
ranges from about 1.0 pm to about 15.0 pm in diameter 15 wise, all amounts are given in grams.
are generally preferred. For inhalation administration a
EXAMPLE 1
microsphere size range of from about 1.0 pm to about

5.0 pm in diameter is preferred. For injectable adminis

To a solution of hydroxyethyl starch (HES) (HES

tration a microsphere size range of about 8.0 pm to
PAN, a trademark of American Critical Care) in dry,
about 15.0 pm in diameter is preferred.
20 distilled N,N’-dimethylacetamide (DMAA) at approxi
The size of the resulting microspheres depends on the
mately 0° C., a measured amount of distilled acryloyl
size of the aqueous droplets in the water-in-oil emulsion.
chloride was added in small portions along with an
The size of the droplets in turn is dependent upon the
equimolar amount of triethylamine, over approximately
shear stress which is applied by the stirrer. The stirrer
a 30 minute time period. The reaction vessel was main
opposes the coalescing tendencies caused by surface 25 tained at this temperature and the reaction proceeded
tension. Generally, the size of the droplets is reduced by
for approximately 2 additional hours. The reaction mix
applying a higher shear stress. A higher shear stress is
ture was then transferred to a vessel containing 200 ml
achieved either by using a higher stirrer speed or by
of acetone at about 0° C. to about 5° C. to precipitate the
increasing the ratio between the viscosities of the con
polymer. The polymer was washed with acetone, dried
tinuous phase and the dispersed phase. A higher viscos 30 with air suction, dissolved in water and reprecipitated in
ity of the continuous phase may be achieved by increas
acetone. Derivatized HES (acryloyl-HES) was finally

ing the proportion of hydrocarbons with more carbon
atoms in the emulsion, e.g., octane, dioxane, dodecane
and the like. The viscosity of the aqueous dispersed

puri?ed by preparative gel permeation chromatography
in water and then freeze-dried. Ratios of the reactants
and the data on the resulting polymers are presented in

phase may be adjusted by using a different molecular 35 Table l. The symbol mwA represents the molecular
weight equivalent of the biodegradable hydrophilic
mer. Adjustment of the viscosity of the aqueous dis
polymer per vinyl group. D.D. represents the degree of

weight of the starting biodegradable hydrophilic poly

persed phase in this manner allows for use of the same
total gel matrix and monovinyl monomer concentra
tion.

Another advantageous feature of the present inven
tion is the fact that the incorporated macromolecular
agents are released from the gel matrix by a diffusion

derivatization in millimole/gram.
TABLE I
Preparation of Acgloyl-HES
la

lb

10

1d

HES
DMAA

5.0
18.8

5.0
18.8

5.0
18.8

5.0
18.8

matrix. The crosslinking density of the matrix may be

Acryloyl chloride
Triethylamine
Acryloyl-HES (yield)
D.D. (mmole/gram)

0.1
0.1 l
4.3
0.07

0.2
0.22
4.3
0.17

0.4
0.45
4.6
0.26

1.0
1.1
5.1
0.62

varied by selecting a biodegradable hydrophilic poly

mwA

14,300

6,000

3,800

1,600

through the crosslinked hydrogel network. Various
rates of release of the macromolecular agents may be 45

achieved by varying the crosslinking density of the gel
mer with varying degrees of derivatization (DD). De
grees of derivatization are used to indicate the average 50

EXAMPLE 2
distance between the attached vinylic groups. A suit
able crosslinking density is also dependent on the mo
Approximately 4.05 grams of partially hydrolyzed
lecular weight of the macromolecular agent and on the
amylopectin was dissolved in 80 ml of water. The solu
desired rate of its release.
tion was cooled to 0° C. and the solution of 1.8 grams of
The degree of derivatization is preferably in the range 55 acryloyl chloride in 10 ml of acetone was added in small
of about 0.01 to about 0.20 mole of vinyl groups per
portions during stirring along with 10 ml of 2N solution
mole of monomer units of the biodegradable hydro
of NaOH so that the solution was remained alkaline.

philic starting polymer. Preferably, there are about 0.02

After approximately 30 minutes the acryloyl-amylopec

to about 0.15 mole of vinyl groups per mole of mono

tin was precipitated with acetone and further processed

mer units of the starting polymer. If hydroxyethyl 60 in a manner similar to Example 1. The yield was 3.9
starch (HES) is used as the starting biodegradable hy
grams and the DD. was 0.32 mmole/gram.
drophilic polymer, the broad range of about 0.01 to
about 0.20 corresponds to a molecular weight of the

EXAMPLE 3
Approximately 5.0 grams of HES was dissolved in
20,000 to about 1000, respectively. About 0.02 to about 65 18.8 grams of DMAA and to this solution was added 6
0.15 corresponds to a molecular weight range of the
ml of 2N solution of NaOH, 50 mg of 4-methoxyphenol

average segment between crosslinking points of about

average segment between the crosslinking points of
about 10,000 to about 1,800. The range in cross-linking

and 1.4 grams of allylglycidyl ether. The resulting mix
ture was stirred for 20 hours at room temperature and

4,741,872
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then processed in a manner similar to Example 1. The
yield was 4.3 grams and ‘the DD. was 0.42 mmole/
gram.

12
TABLE II-continued
Reaction conditions and characteristics of the product

EXAMPLE 4

Protein

a

b

c

d

4.7

4.5

22.8

9.4

e

f

g

h

content %

Approximately 4.3 grams of poIy-[N-(Z-hydroxye
thyl)-L-glutamine], (PHEG), in 18.8 grams of DMAA
was reacted with 0.4 grams of acryloyl chloride in a

EXAMPLE 6

procedure similar to that used in Example 1. The yield
of acryloyl-PHEG was 4.2 grams and the DD. was 0.32

Example 6 was conducted in a manner similar to

mmole/gram.

Example 5, except that the product was washed with

Acryloyl-HES, prepared according to Example 1,
acrylamide and alpha-l-proteinase inhibitor (alpha-l

heptane, then washed with cyclohexane and ?nally
freeze-dried from cyclohexane. The resulting micro
spheres exhibited properties analogous to those found in
Example 5 but contained essentially all of the protein

PI) were dissolved in 0.05 mole/liter ammonium car

which had been initially added in the dispersed phase.

EXAMPLE 5

bonate buffer pH 7.4, together with ammonium persul

EXAMPLE 7

phate (2% mole/mole in terms of the total concentra
tion of vinyl groups). The solution was deoxygenated
by repeated evacuation and ?lling of the vessel with

Approximately 1.6 grams of acryloyl-PHEG, pre
pared according to Example 4, 0.58 gram of N-vinyl-2
pyrrolidone and 0.49 gram of alpha-l-proteinase inhibi
tor (alpha-l-PI) in 13.5 ml of 0.05 mole/liter phosphate

nitrogen at 0° C. The deoxygenated solution was ?l
tered and the ?ltrate was transferred to a polymeriza

tion reactor containing 60 ml of organic continuous

buffer pH 7.4 were used as a dispersed phase to prepare
microspheres in a manner similar to that set forth in

phase. The organic continuous phase was composed of

a mixture of heptane, USP, mineral oil and 0.3 gram of 25 Example 5d. The resulting microspheres had an average
50-15 (sorbitan oleate). The entire mixture was then
diameter of 6.7 pm and a protein content of 11.2%.
?ushed with nitrogen at 0° C. Table II provides a de-:
EXAMPLE 8
scription of the compositions of the dispersed and con
tinuous phases. In Table II, average diameter (pm)
Approximately 50 mg of microspheres prepared in a

represents the average diameter of the microspheres
after rehydration in 0.15 mole/liter NaCl and 0.05
mole/liter phosphate pH 7.4. The protein content %
represents the content of the diffusion releasable protein

suspended in 10 ml 0.05 mole/liter phosphate buffer pH

in dry microspheres.

incubated'at 37° C. with continuous agitation. Samples

manner similar to that used in Examples Sa-d were

7.4 with 0.15 mole/liter NaCl and 0.02% NaN3. The
suspensions were placed in capped test tubes and were

The polymerization reactor consisted of a jacketed
glass vess'el equipped with a controlled-speed stirrer.

of the suspensions were withdrawn at convenient inter

vals and the microspheres were separated by centrifuga

Ports for addition of reactants and withdrawal of sam
ples as well as nitrogen inlet were provided in the ves

tion. The residual amount of the protein in the micro

spheres, the concentration of protein in microspheres

sel-top assembly. When a stable emulsion of the aqueous

and the concentration of protein in the incubation me
dium were determined using the method of Lowry et al.

dispersed phase in the organic continuous phase was
obtained by the action of the stirrer, approximately 0.15
ml of N,N,N',N'-tetramethylenediamine (TEMED)

(OH. Lowry et al., J. Biol. Chem, 193: 265, 1951). The
amount of alpha-l-PI released as function of time is
presented in FIG. 2. FIG. 3 describes the cumulative

was added to the emulsion and the reaction proceeded
at about 0° to 2° C. for another 20 minutes. The result

ing suspension of microspheres was poured in 200 ml of 45 release of alpha-l-PI from HES-polyacrylamide micro
spheres in pg of protein per mg of spheres. The incuba
cold heptane (0°—5° C.), washed with heptane, resus
tion time is plotted in a square root scale. Characteris
pended in ammonium carbonate buffer containing 0.1%
tics of microspheres are those as in Table 2. Characteris
of Triton-X400, washed with pure ammonium carbon
tics
of the microspheres corresponds to those given in
ate buffer (0.01 mole/liter) and freeze-dried.
50 Example Sa-d.
TABLE II

While this invention has been described and illus
trated with reference to certain preferred embodiments
thereof, those skilled in the art will appreciate that vari

Reaction conditions and characteristics of the product
a

b

c

d

e

f

g

h

ous changes, modi?cations and substitutions can be

Dispersed

phase:

55

AcryloylHES
Acrylamide
Alpha-l-Pl
Buffer

1.76

1.76

1.76

2.00

2.00

2.00

2.00

2.00

0.40 0.40 0.40 0.50 0.50 0.50 0.50
0.34 0.34 2.20 0.60 0.60 0.60 0.60
17.50 17.50 15.60 16.90 16.90 16.90 16.90

0.50
0.60
16.90

mwA

3,800 6,000 3,800 3,800 6,000 6,000 6,000 6,000

Continuous

Heptane (ml)
Mineral oil

17
43

17
43

17
43

17
43

17
43

17
43

40
20

10
50

(rpm)

Average
diameter

(um)

cally entraoped therein, said microsphere being able to
release the macromolecular agent at a controlled rate,

comprising emulsifying a vinyl derivative of a biode

(ml)
Stirring

made therein without departing from the spirit of the
invention. It is intended, therefore, that the invention be
limited only by the scope of the claims which follow.
What is claimed is:
1. A method for preparing biodegradable micro
spheres having a three-dimensional network in which
biologically active macromolecular agents are physi

1,600 1,600 1,600 1,600
8.6

14.0

12.5

7.6

800 2,200 2,200 2,200 65
28.0

5.3

46.0

3.6

gradable hydrophilic polymer, a water-soluble monovi
nyl monomer and a biologically active macromolecule

in water, and copolymerizing the biodegradable hydro
philic polymer and the water-soluble monovinyl mono

13
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mer such that the biologically active macromolecule is
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derivatives of proteinaceous polymers, polypeptides,
polyesters, and polyorthoesters.

entrapped therein.
2. The method according to claim 1, wherein the

5. The method according to claim 4, wherein the

biodegradable hydrophilic polymer is prepared by the

biodegradable hydrophilic polymer is a polysaccharide.
6. The method according to claim 5, wherein the

copolymerization of a vinyl derivative of a biodegrad
able hydrophilic polymer which contains at least two
vinyl groups or substituted vinyl groups per average

polysaccharide is a starch derivative.

.

7. The method according to claim 4, wherein the

biodegradable hydrophilic polymer is a polypeptide.

polymer chain.

8. The method according to claim 7, wherein the

3. The method according to claim 2, wherein the

polypeptide is poly-(N—hydroxyalkyl)asparagine or

vinyl derivative of the biodegradable hydrophilic poly

poly-(N-hydroxyalkyDglutamine.

mer has the formula:

9. The method according to claim 1, wherein the
water-soluble monovinyl monomer is selected from the
group consisting of hydrophilic esters and/or amides of

CH2=CRl—(CH2)n—X

(I)
15

wherein R1 is a hydrogen atom or a methyl group; n is

acrylic or methacrylic acids, water-soluble vinyl deriv
atives, acrylic acid and methacrylic acid.
10. The method according to claim 1, wherein the

O, l or 2; X is a radical having the formula:

ratio between the biodegradable hydrophilic polymer
to the water-soluble monovinyl monomer is in the range
of about 1:5 to about 40:1 on a weight basis.

11. The method according to claim 1, wherein the
biologically active macromolecular agent is a hormone,
protein, peptide, vaccine, enzyme or enzyme inhibitor.
and R2 represents the biodegradable hydrophilic poly
12. The method according to claim 1, wherein the
mer which contains at least two vinyl or substituted
25 polymerization is conducted at a temperature of about
vinyl groups per average polymer chain.
0° C. to about 50° C.

4. The method according to claim 3, wherein the

13. The method according to claim 1, wherein the

biodegradable hydrophilic polymer is selected from the
group consisting of polysaccharides, proteinaceous pol

polymerization is conducted using the bead polymeriza

tion technique.

ymers, soluble derivatives of polysaccharides, soluble 30

35

45

55

65
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